158 related articles for article (PubMed ID: 36215514)
1. Pretargeting: A Path Forward for Radioimmunotherapy.
Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in pretargeted radioimmunotherapy.
Gruaz-Guyon A; Raguin O; Barbet J
Curr Med Chem; 2005; 12(3):319-38. PubMed ID: 15723622
[TBL] [Abstract][Full Text] [Related]
4. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
[TBL] [Abstract][Full Text] [Related]
5. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted radioimmunotherapy.
Meredith RF; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
[TBL] [Abstract][Full Text] [Related]
7. Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.
Jallinoja VIJ; Houghton JL
J Nucl Med; 2021 Sep; 62(9):1200-1206. PubMed ID: 34016727
[TBL] [Abstract][Full Text] [Related]
8. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
Au KM; Tripathy A; Lin CP; Wagner K; Hong S; Wang AZ; Park SI
ACS Nano; 2018 Feb; 12(2):1544-1563. PubMed ID: 29361211
[TBL] [Abstract][Full Text] [Related]
9. Radioactive antibodies: a historical review of selective targeting and treatment of cancer.
Goldenberg DM; Sharkey RM
Hosp Pract (1995); 2010; 38(3):82-93. PubMed ID: 20890056
[TBL] [Abstract][Full Text] [Related]
10. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
12. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
13. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
[TBL] [Abstract][Full Text] [Related]
14. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
15. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
17. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
19. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Chang CH; Sharkey RM; Rossi EA; Karacay H; McBride W; Hansen HJ; Chatal JF; Barbet J; Goldenberg DM
Mol Cancer Ther; 2002 May; 1(7):553-63. PubMed ID: 12479274
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
